Ladirubicin
| Code | Size | Price |
|---|
| TAR-T32534-5mg | 5mg | £1,813.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T32534-50mg | 50mg | £3,589.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T32534-100mg | 100mg | £4,970.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Ladirubicin, as an anthracyclines analog is the leading compound of alkylcyclines.
CAS:
171047-47-5
Formula:
C29H31NO11S
Molecular Weight:
601.62
Purity:
0.98
SMILES:
C[C@@H]1O[C@H](C[C@@H]([C@@H]1OS(C)(=O)=O)N1CC1)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O
References
1. Soares PI, Dias SJ, Novo CM, Ferreira IM, Borges JP. Doxorubicin vs. ladirubicin: methods for improving osteosarcoma treatment. Mini Rev Med Chem. 2012 Oct;12(12):1239-49. PubMed PMID: 22512558.
2. Pasello M, Hattinger CM, Stoico G, Manara MC, Benini S, Geroni C, Mercuri M, Scotlandi K, Picci P, Serra M. 4-Demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548): a promising new candidate for chemotherapeutic treatment of osteosarcoma patients. Eur J Cancer. 2005 Sep;41(14):2184-95. PubMed PMID: 16140527.
3. Moneta D, Geroni C, Valota O, Grossi P, de Jonge MJ, Brughera M, Colajori E, Ghielmini M, Sessa C. Predicting the maximum-tolerated dose of PNU-159548 (4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin) in humans using CFU-GM clonogenic assays and prospective validation. Eur J Cancer. 2003 Mar;39(5):675-83. PubMed PMID: 12628848.
4. Marchini S, Damia G, Broggini M, Pennella G, Ripamonti M, Marsiglio A, Geroni C. 4-Demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548), a novel anticancer agent active against tumor cell lines with different resistance mechanisms. Cancer Res. 2001 Mar 1;61(5):1991-5. PubMed PMID: 11280757.